CN Patent

CN107849028A — 3‑(6‑(1‑(2,2‑二氟苯并[d][1,3]间二氧杂环戊烯‑5‑基)环丙烷甲酰氨基)‑3‑甲基吡啶‑2‑基)苯甲酸的新晶型及其制备方法

Assigned to Crystal Pharmatech Co Ltd · Expires 2018-03-27 · 8y expired

What this patent protects

本发明提供3‑(6‑(1‑(2,2‑二氟苯并[D][1,3]间二氧杂环戊烯‑5‑基)环丙烷甲酰氨基)‑3‑甲基吡啶‑2‑基)苯甲酸的晶型A及其制备方法。本发明提供的晶型A引湿性低，方便保存且稳定性好，比之现有技术溶解度更高，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明提供3‑(6‑(1‑(2,2‑二氟苯并[D][1,3]间二氧杂环戊烯‑5‑基)环丙烷甲酰氨基)‑3‑甲基吡啶‑2‑基)苯甲酸的晶型A及其制备方法。本发明提供的晶型A引湿性低，方便保存且稳定性好，比之现有技术溶解度更高，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN107849028A
Jurisdiction
CN
Classification
—
Expires
2018-03-27
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.